US 12,465,578 B2
Substituted alpha-ethyl phenylalkylamines
Paul F. Daley, El Sobrante, CA (US); and Nicholas V. Cozzi, Slinger, WI (US)
Assigned to Alexander Shulgin Research Institute, Inc., Lafayette, CA (US)
Appl. No. 18/695,071
Filed by Alexander Shulgin Research Institute, Inc., Lafayette, CA (US)
PCT Filed Sep. 26, 2022, PCT No. PCT/US2022/044771
§ 371(c)(1), (2) Date Mar. 25, 2024,
PCT Pub. No. WO2023/049480, PCT Pub. Date Mar. 30, 2023.
Claims priority of provisional application 63/248,450, filed on Sep. 25, 2021.
Prior Publication US 2024/0408038 A1, Dec. 12, 2024
Int. Cl. A61K 31/137 (2006.01); A61K 45/06 (2006.01); C07C 217/60 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 45/06 (2013.01); C07C 217/60 (2013.01); C07B 2200/05 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A compound of Formula (A):

OG Complex Work Unit Chemistry
or an enantiomer or enantiomerically enriched mixture thereof, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate of any of the foregoing, wherein:
R1 is —CH3, —CD3, or —CF3;
R2 is —CH3, —CD3, or —CF3; and
X is —CH3, —CD3, or —CF3;
provided that when both R1 and R2 are —CH3, X is —CD3 or —CF3.